Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

524.30 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug ↗
Viking Therapeutics stock falls despite seemingly positive test results for a drug that treats a serious liver disease. 
Via Investor's Business Daily
News headline image
The Week Ahead: What's Next ↗
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. 
Via Talk Markets
News headline image
Is Madrigal Pharmaceuticals Stock a Buy? ↗
It's not the most prominent biotech, but it has an important claim to fame. 
Via The Motley Fool
News headline image
MDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024 ↗
MDGL stock results show that Madrigal Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
2 Under-the-Radar Growth Stocks to Consider ↗
Don't ignore these innovative companies. 
Via The Motley Fool
News headline image
1 No-Brainer Growth Stock to Buy Now ↗
This liver-disease specialist might be significantly undervalued. 
Via The Motley Fool
News headline image
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock ↗
This biotech just got clearance to dive into a deep ocean of a market. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
6 Stocks Positioned to Soar as Investors Focus on MASH
Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of... 
Via TheNewswire.com
News headline image
7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024 ↗
Analyst-backed stocks have a high correlation with future stock price growth. Here are seven stocks with a high number of recent upgrades. 
Via InvestorPlace
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/15 Morning Trading
Via Investor Brand Network
News headline image
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics ↗
These businesses should see good times ahead. 
Via The Motley Fool
News headline image
The 3 Best Biotech Stocks to Buy in April 2024 ↗
Biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. 
Via InvestorPlace
News headline image
2 Top Biotech Buyout Candidates ↗
Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be... 
Via Talk Markets
News headline image
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals ↗
Both stocks are pretty risky, but one of them more so than the other. 
Via The Motley Fool
News headline image
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? ↗
Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off? 
Via The Motley Fool
News headline image
7 Stocks That Will Drive the Weight Loss Drugs Market
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis. 
Via MarketBeat
News headline image
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? ↗
The mid-cap biotech has succeeded where many others failed. 
Via The Motley Fool
News headline image
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? ↗
Madrigal has one key advantage over its two huge potential future rivals. 
Via The Motley Fool
News headline image
7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
News headline image
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? ↗
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
Via The Motley Fool
News headline image
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. 
Via Benzinga
News headline image
FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring ↗
FDA's accelerated approval for Madrigal Pharmaceuticals' Rezdiffra for noncirrhotic nonalcoholic steatohepatitis with liver scarring. The first treatment for liver scarring due to fatty liver disease.... 
Via Benzinga
News headline image
Why Is Geron (GERN) Stock Up 94% Today? ↗
Geron stock is on the rise Friday with heavy trading of GERN shares after the company's blood disorder drug got new backing. 
Via InvestorPlace
News headline image
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported... 
Via Benzinga
Topics Stocks
News headline image
MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today ↗
Madrigal Pharmaceuticals stock is up on Friday as MDGL investors celebrate FDA approval of NASH treatment Rezdiffra today. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.